Lisa Astor is the Associate Editorial Director for Targeted Oncology. Astor received her Bachelor of Arts in English Literature from New York University.
One of the most important effects of the positive findings for entrectinib in patients with ROS1 fusion–positive non–small cell lung cancer (NSCLC) is the potential impact on patients with central nervous system (CNS) metastases, according to Robert C. Doebele, MD, PhD.
Promising clinical trial results have been seen with the exploration of new and existing treatment approaches for patients with triple-negative breast cancer (TNBC) on several fronts, including chemotherapy, immunotherapy, novel antibodies, and agents targeting the PI3K/mTOR/AKT pathway, according to David W. Miles, MB BS, BSc, MD. During a presentation at the <em>1st Annual </em>Paris Breast Cancer Conference hosted by the Physicians Education Resource®, LLC, Miles, a consultant medical oncologist at West Hertfordshire Hospitals in England, provided his perspective on potential new treatment options for patients with TNBC.
The novel oncolytic virus Toca 511 (vocimagene amiretrorepvec) and Toca FC (extended-release 5-fluorocytosine [5-FC]) induced durable responses in patients with recurrent glioblastoma multiforme (GBM) and anaplastic astrocytoma (AA), for a median duration of response of 35.1+ months, according to findings from a phase I study presented during the 2017 AACRNCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. In a pooled analysis of 3 phase I studies, the virus also proved to be well tolerated with fewer any-grade adverse events (AEs) than with standard chemotherapy.1
Results of a prospective clinical trial demonstrated that the detection of positive circulating tumor cells in the blood 5 years after hormone receptor-positive, HER2-negative breast cancer diagnosis was associated with an increased risk for late recurrence.
Confirmed responses were demonstrated in 3 patients with soft tissue sarcoma treated with entrectinib in the STARTRK-2 basket trial, according to the results of a case study presented at the 2017 Connective Tissue Oncology Society Annual Meeting that took place in Maui, Hawaii.
The objective response rate with neoadjuvant nivolumab (Opdivo) plus ipilimumab (Yervoy) was almost tripled compared with nivolumab alone in patients with high-risk resectable melanoma, according to preliminary findings from a phase II study presented during the 32nd SITC Annual Meeting.
Dendritic cells are an essential target for generating immunity against cancer due to their ability to manipulate the immune system and there are a number of potential methods by which DCs can be utilized for cancer immunotherapy, according to Karolina Palucka, MD, PhD.
Determining the true nature, causes, and optimal treatment of neuroendocrine tumors is incredibly important for patients, as even though diarrhea can be a symptom of the disease, it is not always the primary cause.
In a call to action to the neuroendocrine tumor clinical community during the 10th Annual NANETS Symposium, presenter Lesley Moody, MBA, addressed the importance of patient-reported outcomes and patient-reported outcome measurements in the everyday care of patients with NETs, beyond clinical trials.
Bringing coordinated multidisciplinary cancer treatment together into one place is ideal to improve care for patients with neuroendocrine tumors (NETs), according to David C. Metz, MD, during the 10th Annual NANETS Symposium.
David Metz, MD, chair of the North American Neuroendocrine Tumor Society, discusses the focus on multidisciplinary care and exciting areas of research being presented during the 10th Annual NANETS Symposium.